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Introduction: Monocarboxylate transporter 1 (MCT1) is an importer of
monocarboxylates such as lactate and pyruvate and a marker of mitochondrial
metabolism. MCT1 is highly expressed in a subgroup of cancer cells to allow
for catabolite uptake from the tumor microenvironment to support mitochondrial
metabolism. We studied the protein expression of MCT1 in a broad group of breast
invasive ductal carcinoma specimens to determine its association with breast cancer
subtypes and outcomes.
Methods: MCT1 expression was evaluated by immunohistochemistry on
tissue micro-arrays (TMA) obtained through our tumor bank. Two hundred and
fifty-seven cases were analyzed: 180 cases were estrogen receptor and/or progesterone
receptor positive (ER+ and/or PR+), 62 cases were human epidermal growth factor
receptor 2 positive (HER2+), and 56 cases were triple negative breast cancers
(TNBC). MCT1 expression was quantified by digital pathology with Aperio software. The
intensity of the staining was measured on a continuous scale (0-black to 255-bright
white) using a co-localization algorithm. Statistical analysis was performed using a linear
mixed model.
Results: High MCT1 expression was more commonly found in TNBC compared
to ER+ and/or PR+ and compared to HER-2+ (p < 0.001). Tumors with an
in-situ component were less likely to stain strongly for MCT1 (p < 0.05). High
nuclear grade was associated with higher MCT1 staining (p < 0.01). Higher T
stage tumors were noted to have a higher expression of MCT1 (p < 0.05). High
MCT1 staining in cancer cells was associated with shorter progression free survival,
increased risk of recurrence, and larger size independent of TNBC status (p < 0.05).
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Conclusion: MCT1 expression, which is a marker of high catabolite uptake and
mitochondrial metabolism, is associated with recurrence in breast invasive ductal
carcinoma. MCT1 expression as quantified with digital image analysis may be useful
as a prognostic biomarker and to design clinical trials using MCT1 inhibitors.
Keywords: triple negative breast cancer, glycolysis, oxidative phosphorylation, lactic acid, tumor
microenvironment
INTRODUCTION
Breast cancer remains the most common cancer diagnosed
and the second most common cause of cancer-related death
in US women in 2016 despite advances in early detection
and novel treatments (Siegel et al., 2016). Risk-stratification
of breast cancer is predominantly based on the presence or
absence of the hormone receptors for estrogen (ER) and
progesterone (PR), overexpression of human epidermal growth
factor receptor 2 (HER2), clinical staging, and in some cases,
selected gene expression profiles. ER and HER2 are both
prognostic biomarkers and are used to predict response to
antiestrogen drugs and HER2 inhibitors.
Human breast cancer has a different metabolic rate compared
to normal breast tissue. Tumors frequently have very high
levels of lactate in their microenvironment, produced by
aerobic glycolysis. Otto Warburg hypothesized that cancer cells
contained dysfunctional mitochondria leading to their inability
to utilize oxidative phosphorylation to generate ATP and forcing
them to use aerobic glycolysis (Koppenol et al., 2011). We now
know that in many cases of human breast cancer, mitochondria
are not dysfunctional and in fact some cancer cells have very high
mitochondrial oxidative phosphorylation (OXPHOS) (Martinez-
Outschoorn et al., 2017). Glycolysis is more energetically
inefficient compared to OXPHOS and why cells within tumors
would utilize glycolysis has remained a paradox (Vander Heiden
et al., 2009).
Detailed characterization of breast tumor metabolism has
revealed that there is intratumoral metabolic heterogeneity
with some cells being glycolytic and generating lactic acid,
while others have high mitochondrial metabolism. Metabolic
heterogeneity might explain the apparent tumor metabolism
paradox since it increases energetic efficiency (Martinez-
Outschoorn et al., 2017). Metabolic heterogeneity can be induced
in experimental models of breast cancer by oxidative stress,
which damages the mitochondria of intratumoral stromal cells
and induces a metabolic switch to aerobic glycolysis (Pavlides
et al., 2009; Martinez-Outschoorn et al., 2012). Conversely high
antioxidant activity via activation of the pentose phosphate
pathway in a subgroup of carcinoma cells allows these cells
to maintain high mitochondrial oxidative phosphorylation
metabolism (OXPHOS) (Ko et al., 2016). Lactate is one of the
links between these two intratumoral compartments since it can
Abbreviations: MCT, monocarboxylate transporter; TNBC, triple negative breast
cancer; ER, estrogen receptor; PR, progesterone receptor; BLBC, basal like breast
cancer; CK, cytokeratin; ATP, adenosine triphosphate; GIST, gastrointestinal
stromal tumor; AJCC, American Joint Committee on Cancer; ISH, in-situ
hybridization.
be produced by glycolytic tumor stromal cells and then taken up
by carcinoma cells to be utilized for mitochondrial OXPHOS and
ATP production (DeNicola and Cantley, 2015).
Monocarboxylate transporters (MCTs) play a key role in this
symbiotic relationship between carcinoma cells and other cells
of the tumor microenvironment since they regulate the release
and uptake of lactic acid and the extracellular pH of the tumor
(Martinez-Outschoorn et al., 2017). Metabolic reprogramming of
the cancer stroma may provide a compensatory mechanism for
cancer cells to survive in an energetically efficient manner in the
harsh tumor environment. Lactate is mainly taken up by cancer
and non-cancer cells via monocarboxylate transporter 1 (MCT1)
(Pinheiro et al., 2010a, 2012; Jones and Morris, 2016). Cancer
cells frequently express MCT1 (Peiris-Pages et al., 2016).
MCT1 has been correlated with increased disease
aggressiveness across various solid malignancies. Previous
work has shown that MCT1 is expressed in human breast,
ovarian, cervical, lung, and colorectal cancers, highlighting its
importance as a potential marker and therapeutic target across
multiple tumor types (Pinheiro et al., 2010b). Pinhero et al.
have also specifically showed an increase in MCT1 expression
in basal-like breast cancer (BLBC) (Pinheiro et al., 2010a).
Cytokeratin 5 is positive in BLBC and the majority of BLBC are
triple negative breast cancers since they are negative for ER, PR,
and HER2 (Fadare and Tavassoli, 2008).
MCT1 is associated with aggressive disease in models
of breast, gastrointestinal, and squamous cell carcinomas
(Koukourakis et al., 2006; Bonuccelli et al., 2010; Pinheiro
et al., 2010a; Martinez-Outschoorn et al., 2011). In breast cancer
models, fibroblasts surrounding malignant cells demonstrate low
caveolin 1 expression, a loss which enhances aerobic glycolysis
in these cells, with concurrent increased mitochondrial activity
and high expression of MCT1 transporter in the epithelial cancer
cells with uptake of catabolites (Bonuccelli et al., 2010). In a study
carried out by Oliveira et al. expression of MCT1 and MCT4
was present in 90% of GISTs, findings concordant with the high
degree of glycolytic metabolism in these tumor types (de Oliveira
et al., 2012). Also, MCT1 was found in both the carcinoma cell
compartment as well as proliferating basal stem cells in head and
neck cancers, underscoring its importance in cell proliferation
(Curry et al., 2013).
We hypothesized that altered tumor metabolism with high
monocarboxylate uptake in carcinoma cells is a feature of
aggressive breast cancers and that higher MCT1 expression will
be found in cancer cells of this clinical subtype. This is in keeping
with the observations of others that MCT1 is expressed in basal-
like breast cancer. To evaluate this hypothesis, we stained breast
cancer tissue microarrays totaling 257 patients for MCT1 and
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digitally analyzed the expression patterns. We have furthermore




The Institutional Review Board at Thomas Jefferson University
approved the protocol for this study. Samples of breast cancer
were obtained from 257 subjects at Thomas Jefferson University
Hospital. Patient data were collected including age, sex, staging
by AJCC Version 7 criteria, size of the primary tumor, number of
positive lymph nodes, grade, histologic subtypes, mitotic index,
Ki67, lymphovascular invasion, resection margins (if applicable),
treatment including the use of chemotherapy, radiation therapy,
and hormonal therapy, recurrence, and vital status (Edge et al.,
2010).
With respect to hormone receptor status, >1% of cells
positive by immunohistochemistry were consider to be positive
for both estrogen receptor and progesterone receptor status.
For HER2 status, the current guidelines of 3+ staining by
immunohistochemistry with >30% of invasive tumor cells
showing staining, ISH positive based on single probe average
HER2 copy number of >= 6 signals/cell, or ISH positive based
on dual probe HER2 to CEP17 ratio>= 2.0 were used as cut-offs.
Samples and Immunohistochemistry
A total of 532 human samples of breast carcinomawere studied to
evaluate the metabolism of cancer cells within the tumor samples
representative of 257 distinct patients. When possible, samples
were run in duplicate or triplicate based on the amount of tissue
present in the remaining pathology specimens.
Samples were stained by immunohistochemistry for MCT1.
All cancer present on a slide and its dominant staining pattern
were considered when determining the percent of immune-
positive cancer cells in a sample. Human tissues for analysis
were fixed in neutral buffered formalin and then embedded in
paraffin. Sections (4 µm) were dewaxed, rehydrated through
graded ethanols, and antigen retrieval was performed on the
Ventana Discovery ULTRA staining platform using Discovery
CCI (Ventana cat#950-500) for a total application time of 64min,
followed by MCT1 antibody incubation for 45 min. Secondary
immunostaining used a Horseradish Peroxidase (HRP) multimer
cocktail (Ventana cat#760-500) and immune complexes were
visualized using the ultraViewUniversal DAB (diaminobenzidine
tetrahydrochloride) Detection Kit (Ventana cat#760-500). Slides
were then washed with a Tris based reaction buffer (Ventana
cat#950-300) and stained with Hematoxylin II (Ventana cat
#790-2208) for 8 min.
Quantitative analysis of MCT1 was also performed employing
digital pathology with Aperio software. Tissue sections were
scanned on a ScanScope
TM
XT with an average scan time of
120 s (compression quality 70). Images were analyzed using the
Color Deconvolution, the Colocalization, and the Membrane
Aperio Image Analysis tool. For the Color Deconvolution and
Colocalization, analysis areas of staining were color separated
from hematoxylin counter-stained sections and the intensity of
the staining was measured on a continuous scale from 0 (black)
to 255 (bright white). For the membrane analysis, the algorithm
detects the membrane staining for the individual tumor cells in
the selected regions and quantifies the intensity and completeness
of the membrane staining. Tumor cells are individually classified
as 0, 1+, 2+, and 3+ based on their membrane staining intensity
and completeness. A tumor cell is classified 1+ when there is
only partial membrane staining or weak membrane staining. A
tumor cell is classified 2+ when there is moderate and complete
membrane staining. A tumor cell is classified 3+ when there
is intense and complete membrane staining. For each sample
the whole tumor area was analyzed. Tumor specimens were
considered “positive” for MCT1, when greater than or equal to
30% of the cells analyzed stained at an intensity of 2+ or greater,
as previously published (Curry et al., 2013).
Statistical Methods
The expression of MCT1 in human breast specimens was
determined as above. Associations between estrogen receptor,
progesterone receptor, and HER2 expression and the membrane
expression of MCT1 defined as the percentage of cells analyzed
expressing 2+ or greater stain intensity were performed
using multivariate linear regression with adjustment on
heteroskedasticity. Associations of MCT1 expression with race,
menopausal status, histologic and nuclear grade, mitotic score,
histologic subtypes, Ki67 scoring, tumor size, and the presence
of lymphovascular invasion were performed using simple linear
regression analysis. Hazard ratios for both risk of recurrence




Our patients included 257 individuals with a diagnosis of invasive
breast cancer treated at Thomas Jefferson University Hospital
between the years of 2000 and 2008. Characteristics of these
patients are shown in Table 1. The average patient age was 57.2
with a range from 26.9 to 97.8 years. We collected self-identified
information on race of the patients, which included 168 white,
66 black, 10 Asian, 3 Hispanic, and 10 samples where the race is
unknown.Menopausal status was determined by the report of the
patients through review of their medical oncologist’s office notes.
Of the 99 patients for whom this information was recorded, 22
were premenopausal, 22 were listed as peri-menopausal, and 55
were postmenopausal at the time of their initial diagnosis.
With respect to tumor characteristics, 116 patients had T1
tumors, 95 were T2, 16 were T3, 13 were T4, and 17 were
unknown. In 124 patients their lymph nodes were negative,
112 were positive, and 21 were unknown. Only 8 patients had
metastatic disease at the time of diagnosis. The ER, PR, andHER2
characteristics of the subjects are also provided in Table 1.
Association with Receptor Status
Individually, ER, PR, and HER2 positivity were all negatively
associated with MCT1 expression. There is an association
between ER negative status and high MCT1 expression and
between HER2 negative status and high MCT1 expression
(p< 0.003 and 0.045, respectively). There was a trend between PR
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ER and/or PR+ HER2- 138
ER and/or PR+ HER2+ 42
ER and/or PR− HER2+ 20
TNBC 56
IDC, Invasive Ductal Carcinoma; ILD, Invasive Lobular Carcinoma; LN, Lymph Node;
ER/PR, Estrogen/Progesterone Receptor; PR, Progesterone Receptor; HER2, Human
Epidermal Growth Factor Receptor 2 status.
negative status and high MCT1 expression but this did not reach
the level of statistical significance (p < 0.09; Table 2). Thus, we
further investigated TNBC (ER negative, PR negative, and HER2
negative tumors) and found an association between high MCT1
expression and TNBC compared to the other subtypes with an
estimated difference of 27% (p < 0.001; Table 2).
Correlation of Histologic Features with
MCT1 Expression
In addition to receptor status, we also investigated other
histologic features. Tumors with an identifiable in situ
TABLE 2 | Clinico-pathological correlations with MCT1 staining in
epithelial cancer cells.
Characteristic Estimated difference p-value








Triple negative 0.27 < 0.001
Size Odds ratio 0.03 0.002
High mitotic score 0.13 < 0.001
High nuclear grade 0.16 < 0.001
Ki67 0.37 0.715
LVI −0.01 0.833













In situ component identified in the sample −0.09 0.043
ER, estrogen receptor; PR, progesterone receptor; HER2, Human Epidermal Growth
Factor Receptor 2; LVI, Lymphovascular Invasion.
component were less likely to stain strongly for MCT1 (p
= 0.043; Table 2). We therefore also reviewed the presence of
different histologic subtypes for potential correlation with MCT1
expression (Figure 1). There was no statistically significant
correlation with apocrine features (p = 0.891), colloid (p =
0.660), comedo (p = 0.685), cribriform (p = 0.092), lobular (p
= 0.179), metaplastic (p = 0.771), micropapillary (p = 0.815),
mixed histologies (p = 0.159), neuroendocrine (p = 0.633),
pleomorphic (p = 0.13), or tubular subtypes (p = 0.510). It is
important to note that only a small number of samples had any
of these features. In contrast, the presence of a solid subtype
was associated with lower MCT1 staining with an estimated
difference of 11% (p= 0.008, N = 82; Table 2).
High nuclear grade, defined as tumor samples scored as a 3
vs. those scored as either 1 or 2 was significantly associated with
higher MCT1 staining with a p-value of <0.001. Similarly, a high
mitotic score (score of 3 vs. those with scores of 1 and 2) was also
associated with higherMCT1 staining (grade 3 vs. grades 1 and 2)
with p < 0.001. Conversely, the presence of lymphovascular
invasion and Ki67 rates scored by the pathologists were not
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 April 2017 | Volume 5 | Article 27
Johnson et al. Monocarboxylate Metabolism in Breast Cancer
FIGURE 1 | Expression of MCT1 in invasive breast cancer. (A) Invasive ductal carcinoma grade 2. (B) Invasive ductal carcinoma grade 3. (C) Cribriform pattern.
(D) Invasive lobular carcinoma grade 3. Note that the grade 2 invasive ductal carcinoma has lower MCT1 expression compared to the other subtypes. Original
magnification 20x (scale bar 50 µM).
associated with MCT1 expression (p = 0.833 and p = 0.715,
respectively; Table 2).
Correlation of Clinical Features with MCT1
Expression
We also reviewed patient characteristics with regards to MCT1
expression. These included age, self-identified race, menopausal
status, tumor, and lymph node stage by AJCC criteria, and tumor
size (Table 2). No statistically significant differences were noted
in MCT1 expression patterns between racial groups. However,
MCT1 staining was 12% higher in premenopausal women’s
tumors as compared to their post-menopausal counterparts
(p < 0.053). Younger age was statistically associated with higher
MCT1 staining p < 0.001 but the magnitude of this difference
was estimated at only 3% with a confidence interval from 1 to
5%. Thus, this is likely of little clinical significance.
Comparisons were made both by individually comparing T1a,
1b, 1c, 2, 3, 4a, 4b, and 4d and by comparing all T1, 2, 3, and
4 samples. Higher T stage tumors were noted to have a higher
expression of MCT1, as summarized in Table 3. Tumor size,
considered as a continuous variable, was also positively associated
with MCT1 expression with an odds ratio of 0.03 and p-value
of 0.002 (Table 2). Nodal status was not associated with MCT1
expression.
Outcome Correlations Data
At the time of the collection of our data, survival data was
available with an average follow up time of 8.04 years. Seventy-
three patients recurred by the time data was collected at an
average of 4.37 years after diagnosis. Higher MCT1 staining was
predictive of recurrence with a hazard ratio of 2.82 and a p-
value of 0.024 (Table 4, Figure 2). Of the 257 patients presented
here, 196 were alive at the time of data analysis. The overall
survival of the sum of all patients was 5.68 years. MCT1 staining
trended toward an association with overall survival but this was
not statistically significant, with a hazard ratio of 1.89 and p- value
of 0.171 (Table 4).
DISCUSSION
Triple Negative Breast Cancer Is
Associated with Higher Expression of
MCT1
Our work has shown a statistically significant association
between ER negative, HER2-negative, and triple negative breast
cancer and high MCT1 expression. This is in keeping with
the observation by McCleland et al. that 26% of their 31
triple negative samples stained either 2+ or 3+ for MCT1
by IHC (McCleland et al., 2012). Pre-menopausal patients
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TABLE 3 | T stage correlation with MCT1 staining.
AJCC Clinical
Stage
vs. T1 vs. T2 vs. T3 vs. T4
T1 −0.05 (p < 0.18) 0.19 (p < 0.001) 0.21 (p < 0.001)
T2 0.14 (p < 0.04) 0.16 (p < 0.02)
T3 0.02 (p < 0.99)
TABLE 4 | Correlation of MCT1 staining with recurrence and overall
survival using a Cox Regression Model.
Outcome measure Hazard ratio p-value
Recurrence 2.82 0.024
Overall survival 1.89 0.171
FIGURE 2 | Progression Free Survival in patients expressing high MCT1
(≥30%) and low MCT1 (<30%).
(relative to their post-menopausal counterparts) also had a higher
proportion of cells expressing MCT1, although this may in fact
be due to the fact that triple negative disease is more prevalent in
pre-menopausal females. Identifying a metabolic signature that
is associated with these aggressive features provides an additional
insight into this category of breast cancer.
MCT1 Expression Is Associated with Other
Poor Prognostic Markers
Triple negative breast cancer is known to be associated with
African-American race, younger age at diagnosis, higher clinical
stage, higher grade, higher mitotic indices, and pre-menopausal
status (Carey et al., 2007). Similarly, MCT1 staining was
associated with younger age, higher grade, higher mitotic index,
and menopausal status. These are all features of more aggressive
disease regardless of their association with triple negative breast
cancer. Race and clinical stage were not associated.
We have also investigated histologic subtypes as previous
work within triple negative breast cancer has suggested a
difference in aggressiveness based upon these characteristics
(Brower et al., 1995; Jensen and Page, 2003; Go et al., 2010).
With the exception of the solid subtype (−0.11, p = 0.008) there
were no associations found within our cohort of patients. This
is in contrast to other studies showing that the comedo and
pure papillary subtypes may be associated with poor prognostic
markers and increased invasion on biopsy (Brower et al., 1995;
Jensen and Page, 2003; Go et al., 2010). A limitation of this study
may be the small numbers of cases of each subtype with the
exception of the solid subtype. We also do not have information
of gene expression profiling of these tumors in order to determine
if gene expression features are associated with MCT1 expression.
There was an association between MCT1 positivity and larger
tumor size, suggesting that MCT1 promotes increased carcinoma
cell survival and growth (p= 0.002). Studies in other cancers have
also demonstrated a correlation between highMCT1 staining and
advanced tumor stage, particularly in head and neck squamous
cell carcinomas (Curry et al., 2013), gastrointestinal cancers (de
Oliveira et al., 2012), prostate cancer (Pertega-Gomes et al.,
2014), and urothelial cancer (Choi et al., 2014).
MCT1 Expression Is Associated with Poor
Outcomes
IncreasedMCT1 staining was associated with a higher recurrence
rate with a HR of 2.62 (p = 0.024). In addition, the association
between a higher percentage of cells staining for MCT1 and
death had a hazard ration of 1.89, however this result was
not statistically significant (p = 0.171). When we investigated
whether the associations with higher risk of recurrence was
driven by TNBC vs. MCT1 expression, MCT1 expression has an
independent contribution to the chance of recurrence.
One potential explanation is that recurrence of disease is
more likely when the stroma is metabolically primed to host
tumor cells. If chemotherapy failed to eradicate the entirety of
the tumor burden, small satellite colonies may more easily settle
in soil that has metabolically shifted to serve these tumor cells,
thus providing another level of chemo-resistance not previously
delineated. To prevent recurrence in high-risk, triple negative
disease, it may be necessary to target this soil. MCT1 not only
provides diagnostic value but it could serve as an important
therapeutic target in the future where chemotherapy would target
not only the tumor cell but its stromal energy supply as well.
MCT4, a lactate-pyruvate shuttle found in stromal cells, could
be MCT1’s counterpart therapeutic target. Thus, TNBCs may be
further described not only as having a distinct molecular subtype
but potentially a distinct metabolic phenotype that can aid in
diagnosis and prognostication of this group of tumors.
Relevance and Future Directions
The current study is consistent with previous work revealing
an association between MCT1 and aggressive breast cancer.
MCT1 expression in a TNBC in vitro model is associated with
cell migration (Gray et al., 2016). Also, Pinheiro et al. have
discovered an association between MCT1 expression and up-
regulation of basal-associated markers such as CK5, CK14, and
vimentin and an inverse relationship of MCT1 to ER and PR
expression (Pinheiro et al., 2012).We have discovered thatMCT1
is associated with poor outcomes irrespective of breast cancer
subtype. MCT1 expression in carcinoma cells may improve risk-
stratification of breast cancers. For example, high MCT1 staining
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may be a marker of a subgroup of very aggressive breast cancers.
Inhibitors of MCT1 are in development and may prove to be
active in this disease. Our results will need to be evaluated
prospectively to confirm the role of MCT1 as a prognostic and
predictive biomarker in breast cancer.
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